AZD4547

For research use only. Not for use in humans.

目录号:S2801 别名: ABSK 091

AZD4547 Chemical Structure

CAS No. 1035270-39-3

AZD4547 (ABSK 091)是一种新型选择性的FGFR抑制剂,靶向作用于FGFR1/2/3,在无细胞试验中IC50为0.2 nM/2.5 nM/1.8 nM,对FGFR4, VEGFR2(KDR)具有微弱的作用活性,对IGFR, CDK2和p38几乎没有作用活性。Phase 2/3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1801.43 现货
RMB 901.31 现货
RMB 1395.39 现货
RMB 4661.52 现货
RMB 7125.05 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的AZD4547发表文献85篇:

产品安全说明书

FGFR抑制剂选择性比较

生物活性

产品描述 AZD4547 (ABSK 091)是一种新型选择性的FGFR抑制剂,靶向作用于FGFR1/2/3,在无细胞试验中IC50为0.2 nM/2.5 nM/1.8 nM,对FGFR4, VEGFR2(KDR)具有微弱的作用活性,对IGFR, CDK2和p38几乎没有作用活性。Phase 2/3。
特性 AZD4547高选择性作用于 FGFR1-3,比作用于FGFR4选择性高。AZD4547有效作用于野生型和突变型FGFR酪氨酸激酶活性。
靶点
FGFR1 [1]
(Cell-free assay)
FGFR3 [1]
(Cell-free assay)
FGFR2 [1]
(Cell-free assay)
KDR [1]
(Cell-free assay)
0.2 nM 1.8 nM 2.5 nM 24 nM
体外研究

与 FGFR1-3相比, AZD4547作用于FGFR4,活性微弱,IC50为165 nM。AZD4547 只抑制重组 VEGFR2 (KDR) 激酶活性, IC50为 24 nM,在体外选择性作用于一组多种代表性的人类激酶。0.1 μM AZD4547 作用于一系列重组激酶,包括 ALK, CHK1, EGFR, MAPK1, MEK1, p70S6K, PDGFR, PKB, Src, Tie2,和 PI3K,没有作用活性。相应地,在细胞磷酸化实验中,可观察到AZD4547 作用于FGFR1-3的选择性比作用于 FGFR4, IGFR, 和 KDR高。AZD4547在体外,只有作用于表达去调控FGFRs 如KG1a, Sum52-PE,和KMS11的肿瘤细胞,具有有效抗增殖活性,IC50 为18-281 nM,而对MCF7 及100 种以上其他肿瘤细胞无活性。AZD4547 处理人类肿瘤细胞,有效抑制FGFR 和 MAPK 磷酸化,这种作用存在剂量依赖性。AZD4547 也有效抑制FRS2 和 PLCγ磷酸化,及下游FGFR信号。另外, AZD4547作用于乳腺细胞系,MCF7和Sum52-PE 而不是KG1a和 KMS11细胞,影响AKT磷酸化。AZD4547处理Sum52-PE 和 KMS11细胞,显著诱导凋亡,作用于KG1a细胞,显著提高细胞周期在G1期停滞而不是凋亡, 而作用于MCF7细胞,对细胞周期分布和凋亡都没有作用效果。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SNU449 Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL3SG9kPzJiaB?= M3PLPGlEPTB;MD6wPFIh|ryP NWC2VVR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjBpPkK2N|UyOzJyPD;hQi=>
SK-HEP-1 M2LFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13YZlczKGh? MYnJR|UxRTBwMEi0JO69VQ>? MlTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUGzNlAoRjJ4M{WxN|IxRC:jPh?=
SNU475 Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHnWWg4OiCq NHuxR2pKSzVyPUWuOEDPxE1? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ|NUGzNlA9N2F-
Hep3B NV;s[o5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzOO|IhcA>? MWfJR|UxRTZwNEOg{txO MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ|NUGzNlA9N2F-
PLC/PRF5 NWPXSGZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETWOZA4OiCq M120[GlEPTB;Nj61OUDPxE1? M2fqSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN|IxLz5{NkO1NVMzODxxYU6=
Hur7 NYjoSnNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLNO|IhcA>? MmfVTWM2OD15LkK1JO69VQ>? NHnUOZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOCd-Mk[zOVE{OjB:L3G+
HepG2 MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;tO|IhcA>? MXfJR|UxRThwN{Og{txO MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ|NUGzNlA9N2F-
SNU449 MlnkR4xwdm:pZX7pZ{Bie3OjeR?= NXj6TGlwOSEEtV2= MUiyOEBp NEK5d5ll\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7 NHHpRpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOCd-Mk[zOVE{OjB:L3G+
SK-HEP-1 M17KN2Ntd26xZ3XubYMh[XO|YYm= NVrJS44xOSEEtV2= MVmyOEBp NWLIZmNn\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueR?= NEjvWpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOCd-Mk[zOVE{OjB:L3G+
SNU449 MUPGeY5kfGmxbjDBd5NigQ>? MknCNE0zKM7:TR?= NGT4Sok1QCCq MnLPZ4F2e2W|IHGg[IVkemWjc3Wgc4YhTlKVMv-8kGFMXCxiYX7kJGVTUyCyaH;zdIhwenmuYYTpc44> MmXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUGzNlAoRjJ4M{WxN|IxRC:jPh?=
SK-HEP-1 NEjTWG9HfW6ldHnvckBCe3OjeR?= NVvwXZV{OC1{IN88US=> M2e3VFQ5KGh? MXfjZZV{\XNiYTDk[YNz\WG|ZTDv[kBHWlN{78{MRWtVNCCjbnSgSXJMKHCqb4PwbI9zgWyjdHnvci=> M1vtUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN|IxLz5{NkO1NVMzODxxYU6=
BaF3 FLT3-TEL MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfHS2k2OD12Lk[gxtEhOC53N{eg{txO MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
BaF3 RET-TEL M{Gw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX21N3doT0l3ME2wMlM6KMLzIECuNFQ5KM7:TR?= M2G2flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mkm0O|QyLz5{NkK5OFc1OTxxYU6=
BaF3 Parental NVTETJNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C1TWdKPTExubWxNEDPxE1? NXPR[W0{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPVQ4PDFpPkK2Nlk1PzRzPD;hQi=>
MOLM14 FLT3/ITD MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\WSZFIUTVyPUCuOFg1KMLzIECuNVU4KM7:TR?= NFu5Tlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK5OFc1OSd-Mk[yPVQ4PDF:L3G+
MV4-11 FLT3/ITD MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLzeGZIUTVyPUCuOFU6KMLzIECuNFQ3KM7:TR?= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
TT RET C634W MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37zTWdKPTB;Mj65JOKyKDBwOUC0JO69VQ>? MnHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O|QyRC:jPh?=
AN3-CA FGFR2 N550K, K310R Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7sS2k2OD1yLkCzNUDDuSByLkCyN{DPxE1? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
MFE296 FGFR2 N550K NVX0ZnJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULDVmU4T0l3ME2wMlc{OCEEsTCwMlA2PyEQvF2= NFLXOGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK5OFc1OSd-Mk[yPVQ4PDF:L3G+
MFE280 FGFR2 S252W MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjtS2k2OD1yLkKxPEDDuSByLkC3N{DPxE1? NHLVcmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK5OFc1OSd-Mk[yPVQ4PDF:L3G+
Ishikawa FGFF2 over exp. MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqzTFVIUTVyPUSuOUDDuSBzLkWxJO69VQ>? M1\UVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mkm0O|QyLz5{NkK5OFc1OTxxYU6=
HEC1A Normal FGFR2 NFvZTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHHTVUx97nnMUCg{txO M4\hUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mkm0O|QyLz5{NkK5OFc1OTxxYU6=
A549 NEfmeZZE\WyuII\pZYJqdGm2eTDBd5NigQ>? MUKwMlEwOSEQvF2= M2ixbFQ5KGh? NXPkWJJC\W6qYX7j[ZMhTXKub4TpcoljKGmwZIXj[YQhfmmjYnnsbZR6KGyxc4O= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3M{CyNEc,OjZyNUOwNlA9N2F-
SGC-7901 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzQUZMyKG6PLUGwJO69VQ>? MYW3NkBp MWjJR|UxKG:oIEWtNVAh|ryPLDDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M{LzU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe2PVE2Lz5{NUW3OlkyPTxxYU6=
HGC-27 NHzlZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\QUlEhdk1vMUCg{txO NHXsXZo4OiCq NEW2coFKSzVyIH;mJFUuOTBizszNMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M3rTXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe2PVE2Lz5{NUW3OlkyPTxxYU6=
MKN-28 M{\LZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37nOlEhdk1vMUCg{txO NGryVmo4OiCq NGfHeVJKSzVyIH;mJFUuOTBizszNMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MlfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3N{[5NVUoRjJ3NUe2PVE2RC:jPh?=
NCI-N87 NFvCeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHwbZYyKG6PLUGwJO69VQ>? NVvRZVNIPzJiaB?= MYXJR|UxKG:oIEWtNVAh|ryPLDDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXfoeJBIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O|Y6OTVpPkK1OVc3QTF3PD;hQi=>
KATOIII MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e3UFEhdk1vMUCg{txO NYr6b|hRPzJiaB?= M13xbmlEPTBib3[gNVAuOTByIH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV5NkmxOUc,OjV3N{[5NVU9N2F-
SNU-16 Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTjdGljOSCwTT2xNEDPxE1? MU[3NkBp MnLwTWM2OCCxZjCxNE0yODBibl2sJIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MnT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3N{[5NVUoRjJ3NUe2PVE2RC:jPh?=
4T1 M3jF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnBVYlKSzVyPUCuOlTDuTBwMUGg{txO MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2Mki5N{c,OjR4NEK4PVM9N2F-
MDA-MB-468 NHfHbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITlcYpKSzVyPUSuPeKyOC56NTFOwG0> NXX6eYhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFI5QTNpPkK0OlQzQDl|PD;hQi=>
HCT116 NXW5TIlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe0V2hqUUN3ME2xOU46yrFzLkiyJO69VQ>? MmrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEK4PVMoRjJ2NkSyPFk{RC:jPh?=
SW620 NGPUcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj2TWM2OO,:nkKwJO69VQ>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2Mki5N{c,OjR4NEK4PVM9N2F-
MDA-MB-231 NVLnOWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|Ux97zgMkCg{txO MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2Mki5N{c,OjR4NEK4PVM9N2F-
CT26 NGi1c2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPqRVl1UUN3MP-8olIxKM7:TR?= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2Mki5N{c,OjR4NEK4PVM9N2F-
SW480 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH70WpVKSzVy78{eNlAh|ryP MljpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEK4PVMoRjJ2NkSyPFk{RC:jPh?=
4T1 M1XLPWFxd3C2b4Ppd{BCe3OjeR?= M4DwNVEvOjVvMkCg{txO M1fEVFI1KGh? MkT2bY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= M2KwSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
KG1a NWT4ZXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7je4N2UUN3ME2wMlAyQCEQvF2= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN4OUmyPEc,OjJ|Nkm5Nlg9N2F-
Sum52-PE MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;oSGlEPTB;MD6wOFEh|ryP NUPFTFFpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlk6OjhpPkKyN|Y6QTJ6PD;hQi=>
KMS11 Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMkixJO69VQ>? NFT3fpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2PVkzQCd-MkKzOlk6Ojh:L3G+
MCF7 M4X3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjnUGlKSzVyPkOwJO69VQ>? MknaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|Nkm5NlgoRjJ{M{[5PVI5RC:jPh?=
KG1 MXXGeY5kfGmxbjDhd5NigQ>? MlTqO|IhcHK| NY\Le3Z5UW6qaXLpeIlwdiCxZjDGS2ZTOSCrbjDoeY1idiCNR{GgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjByMEKg{txONg>? MkHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUe0NlcoRjJ5MUG3OFI4RC:jPh?=
RT112 MXvGeY5kfGmxbjDhd5NigQ>? NGTIdpE4OiCqcoO= M3PJWmlvcGmkaYTpc44hd2ZiRlfGVlMhcW5iaIXtZY4hWlRzMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjByME[g{txONg>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{SyO{c,OjdzMUe0Nlc9N2F-
KG1 MmHmRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NEfFNXc4OiCqcoO= M1yxRmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1exJINmdGy|IHX4dJJme3OrbnegSmdHWjFiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4xODF7IN88UU4> NF;XSYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVk{Pyd-Mkm3O|U6Ozd:L3G+
KG1 NYfLU|NMSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NH;oOFg4OiCqcoO= M3nIfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1exJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFQ1utPEBie3OjeTygTWM2OCB;IECuNFA{OyEQvF2u NYLod2Y3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PFczODRpPkK4Olg4OjB2PD;hQi=>
SNU16 MljlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MVG3NkBpenN? NXn5N5hPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTUnUyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgR2NMNThiYYPzZZktKEmFNUCgQUAxNjByM{Sg{txONg>? NXzCTphiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PFczODRpPkK4Olg4OjB2PD;hQi=>
SNU16 NXnqdnlbTnWwY4Tpc44h[XO|YYm= MV[3NkBpenN? MX\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IF\HSnIzKGmwIHj1cYFvKFOQVUG2JINmdGy|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliU2LCM2NEUy16IHHzd4F6NCCLQ{WwJF0hOC5yMEO2JO69VS5? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{SyO{c,OjdzMUe0Nlc9N2F-
SNU16 MV\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NH\RR4M4OiCqcoO= M3fmdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU17VNVYh[2WubIOg[ZhxemW|c3nu[{BHT0[UMjDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjByNkKg{txONg>? M4DYbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1PVM4Lz5{OUe3OVk{PzxxYU6=
KG1 MVfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NEW4VHQ4OiCqcoO= MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF\HSnIyNXS{YX7zcI9k[XSnZDDoeY1idiCNR{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{ivUXRVKGG|c3H5MEBKSzVyIE2gNE4xODZ2IN88UU4> MmC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|NEi1N|coRjJ5M{S4OVM4RC:jPh?=
SNU16 NFPGdoNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MmfFO|IhcHK| MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF\HSnIzNWGvcHzp[olm\CCqdX3hckBUVlVzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhS0ONOD;NWHQh[XO|YYmsJGlEPTBiPTCwMlAyOzRizszNMi=> Mlr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|NEi1N|coRjJ5M{S4OVM4RC:jPh?=
KATO III NGTrbIdHfW6ldHnvckBie3OjeR?= NYP1UHhwPzJiaILz M32zUmlvcGmkaYTpc44hd2ZiRlfGVlIhcW5iaIXtZY4hU0GWTzDJTWkh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IHPlcIwh[2:3boTpcochc2m2LUigZZN{[XluIFnDOVAhRSByLkCxOFEh|ryPLh?= MlPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5MUS2PVIoRjJ6N{G0OlkzRC:jPh?=
KG1 MVHGeY5kfGmxbjDhd5NigQ>? MnnxO|IhcHK| MWDJcohq[mm2aX;uJI9nKE[JRmKxU3AzKG[3c3XkJGZITlJzIHnuJIh2dWGwIFvHNUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliY3XscEBkd3WwdHnu[{BscXRvODDhd5NigSxiSVO1NEA:KDBwMEG2NUDPxE1w M{TTOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G0OlkzLz5{OEexOFY6OjxxYU6=
KATO III Mn7VSpVv[3Srb36gZZN{[Xl? NVnuU3VYPzJiaILz NXLvNmdHUW6qaXLpeIlwdiCxZjDGS2ZTOiCrbjDoeY1idiCNQWTPJGlKUSClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JHNTSi:FQ1utPEBie3OjeTygTWM2OCB;IECuNFIxOiEQvF2u MkPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUe0NlcoRjJ5MUG3OFI4RC:jPh?=
SNU16 MkH1SpVv[3Srb36gZZN{[Xl? NFewUpg4OiCqcoO= MYrJcohq[mm2aX;uJI9nKE[JRmKyJIlvKGi3bXHuJHNPXTF4IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFczKGi{czDifUBk\WyuIHPveY51cW6pIHvpeE05KGG|c3H5MEBKSzVyIE2gNE4xOjV2IN88UU4> NFzqSmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOFY6Oid-Mki3NVQ3QTJ:L3G+
UM-UC-14 NUCyeoRHSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NIK2Sng4OiCqcoO= MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFWPLWXDMVE1KGOnbHzzJIV5eHKnc4PpcochTkeIUkOgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5yMk[5JO69VS5? M1\rUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1PVM4Lz5{OUe3OVk{PzxxYU6=
RT112 NFGyZ5RHfW6ldHnvckBie3OjeR?= M{TzNlczKGi{cx?= NEnJXoNKdmirYnn0bY9vKG:oIF\HSnI{KGmwIHj1cYFvKFKWMUGyJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSClZXzsJINwfW62aX7nJItqfC16IHHzd4F6NCCLQ{WwJF0hOC5yMkeg{txONg>? MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNE[5Nkc,Ojh5MUS2PVI9N2F-
UM-UC-14 NFP1eHlHfW6ldHnvckBie3OjeR?= MkXJO|IhcHK| MVLJcohq[mm2aX;uJI9nKE[JRmKzJI12fGGwdDDpckBpfW2jbjDVUU1WSy1zNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkh[2WubDDjc5VvfGmwZzDrbZQuQCCjc4PhfUwhUUN3MDC9JFAvODJ5MTFOwG0v M3jFbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G0OlkzLz5{OEexOFY6OjxxYU6=
RT112 NFvD[IZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NFjzfYw4OiCqcoO= MmrhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCUVEGxNkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iMD6wNlkzKM7:TT6= NHW5RWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W5PVc1Oid-Mke1PVk4PDJ:L3G+
H1581 MUnGeY5kfGmxbjDhd5NigQ>? NVK3TndQPzJiaILz NGX6XJhKdmirYnn0bY9vKG:oIF\HSnIyKGmwIHj1cYFvKEhzNUixJINmdGy|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliU2LCM2NEUy16IHHzd4F6NCCLQ{WwJF0hOC5yM{K5JO69VS5? MljNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUe0NlcoRjJ5MUG3OFI4RC:jPh?=
NCI-H1581 NVrJPWpjSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= Mn;aO|IhcHK| NYq5RW9ISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF3OEGgZ4VtdHNiZYjwdoV{e2mwZzDGS2ZTOSCjZoTldkA4OiCqcoOsJGlEPTBiPTCwMlA1KM7:TT6= NXSwepZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U6OzdpPkK5O|c2QTN5PD;hQi=>
B16F10 NHT4XHBEgXSxdH;4bYNqfHliYYPzZZk> NUTzWpRpPzJiaILz M4fNR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGIyPkZzMDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yNUGg{txONg>? NXXLN2NZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3N|Y6QTNpPkK1O|M3QTl|PD;hQi=>
A549 NVmw[VBiS3m2b4TvfIlkcXS7IHHzd4F6 M33ISVczKGi{cx?= M{jMfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODZ{IN88UU4> Mnu4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5M{[5PVMoRjJ3N{O2PVk{RC:jPh?=
NCI-H1581 NWHSbGhETnWwY4Tpc44h[XO|YYm= M2\mO|czKGi{cx?= MmLWTY5pcWKrdHnvckBw\iCIR1\SNUBqdiCqdX3hckBPS0lvSEG1PFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IHPlcIwh[2:3boTpcochc2m2LUigZZN{[XluIFnDOVAhRSByLkC2NlYh|ryPLh?= NFfhfnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOFY6Oid-Mki3NVQ3QTJ:L3G+
RT112 MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MVe3NkBpenN? MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKWMUGyJINmdGy|IHX4dJJme3OrbnegSmdHWjNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4xQDN6IN88UU4> M{OyWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1PVM4Lz5{OUe3OVk{PzxxYU6=
RT112 MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mn\pO|IhcHK| M3;rSmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmdHWjNvYX3wcIlncWWmIHj1cYFvKFKWMUGyJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFQ1u4M21VXCCjc4PhfUwhUUN3MDC9JFAvODh6NDFOwG0v NIC2Z3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O0PFU{Pyd-MkezOFg2Ozd:L3G+
NCI-H1581 M{DzfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MonPO|IhcHK| NGnOUZhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGZITlJzLXHtdIxq\mmnZDDoeY1idiCQQ1mtTFE2QDFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNEUzhxTWTUJIF{e2G7LDDJR|UxKD1iMD6wPVIyKM7:TT6= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN2OEWzO{c,Ojd|NEi1N|c9N2F-
HeLa 229 M{[2[mN6fG:2b4jpZ4l1gSCjc4PhfS=> M2PO[VczKGi{cx?= M2DRNmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiMkK5JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkG0JO69VS5? MmDlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5M{[5PVMoRjJ3N{O2PVk{RC:jPh?=
BAF3 Mmm1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NUDUdYdTPzJiaILz NWHrU3g{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXkWJRmKyJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwMkKyJO69VS5? MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{W5N|coRjJ7N{e1PVM4RC:jPh?=
SGC7901 Mn\QRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NYHWO3B[PzJiaILz MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOJQ{e5NFEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuPEDPxE1w NIrVS2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{iyPVUyQSd-Mke4Nlk2OTl:L3G+
MGC803 MWXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MkniO|IhcHK| M2fCUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVfDPFA{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTC2MlIh|ryPLh?= NFHXT5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{iyPVUyQSd-Mke4Nlk2OTl:L3G+
BGC823 M17xNGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M2e1W|czKGi{cx?= NHrZeIVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLHR|gzOyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gO{46KM7:TT6= M3vrXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEK5OVE6Lz5{N{iyPVUyQTxxYU6=
HL7702 NFLBcmZEgXSxdH;4bYNqfHliYYPzZZk> MoixO|IhcHK| M3;n[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPzdyMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOThwMkGg{txONg>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd|Nkm5N{c,OjV5M{[5PVM9N2F-
U-2 OS NW\XUo9reUiWUzDzd4F6 NGi4dHRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz NVzXToRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MlL2dWhVWyC|c3H5 NIDp[2ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 NVH2XYdweUiWUzDzd4F6 MorPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= MoHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 MVHxTHRUKHO|YYm= NY\PS4xWeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz NXvq[GtlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD NEPrNJFyUFSVIIPzZZk> MlnVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ MnP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH MWfxTHRUKHO|YYm= MlrBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NEXZT4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 M2fmWZFJXFNic4PhfS=> NHfSTHJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= M{K4WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 NGP4XJVyUFSVIIPzZZk> MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| M3n4VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
fibroblast cells NFrGOmhyUFSVIIPzZZk> NHXUZopyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiY3;ueJJwdCCKaDD3bYxlKHS7cHWg[oljem:kbHHzeEBk\Wyucx?= NFPGWoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NUnocIN[eUiWUzDzd4F6 NGLpdotyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= Ml7YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 M3n0[ZFJXFNic4PhfS=> MoXXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN? M3HpclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 MlfXdWhVWyC|c3H5 NFLP[WJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> NGfDbIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 MnfUdWhVWyC|c3H5 M1X6c5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz NVLpbHh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 MlfGdWhVWyC|c3H5 M2H3V5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= NUG1[Y57RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18 NULiV5NVeUiWUzDzd4F6 NFfXemFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?= MoLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-FGFR / FGFR1 / p-AKT / AKT / p-ERK / ERK; 

PubMed: 28900173     


Western blots (cropped) are shown for the indicated proteins in MDA-MB-361, BT474, and SKBR3 cells treated with AZD4547 (0, 1, 3, or 5 µM) for 72 hours. 

pFRS2; 

PubMed: 25576915     


AZD4547 inhibits FGFR2 pathway activation in SNU16 and KATOIII cells. Cells were incubated with AZD4547 at the indicated doses. Cell lysates were immunoblotted for phospho-FGFR, phospho-FRS2, phospho- and total AKT, and phospho- and total ERK.

28900173 25576915
Growth inhibition assay
Cell viability; 

PubMed: 28900173     


MDA-MB-361, BT474, and SKBR3 ErbB2-overexpressing breast cancer cells were treated with AZD4547 (0, 0.1, 0.3, 1, 3, or 5 µM) for 5 days. Then the viable fraction of each cell line was determined with an MTS assay. 

Cell viability; 

PubMed: 25576915     


FGFR2-amplified GC cells are selectively sensitive to AZD4547. In vitro CCK-8 assay across a panel of 6 GC cells demonstrated that SNU16 and KATOIII cells were extremely sensitive to AZD4547 with IC50 values of 5-10 nM. Data (n = 6) are presented as mean ± SD.

28900173 25576915
体内研究 AZD4547按3 mg/kg剂量口服处理携带KMS11肿瘤的小鼠,每天两次,与空白对照组相比,显著抑制53%肿瘤生长,AZD4547 按 12.5 mg/kg剂量每天处理一次,或按 6.25 mg/kg剂量每天处理两次,则完全抑制肿瘤,这与p-FGFR3的药效学调节剂量正相关,且降低 KMS11肿瘤细胞增殖。而且, AZD4547按 12.5 mg/kg剂量口服处理给药FGFR1融合KG1a 移植瘤模型,每天一次,抑制65% 肿瘤生长。在有效剂量水平,AZD4547不表现出抗血管生成的效果。AZD4547 对血压没有显著作用效果,因此在体内缺乏 抗-KDR 活性。相应地, AZD4547按6.25 mg/kg剂量口服处理对Cediranib敏感的移植瘤模型,包括 Calu-6, HCT-15 和 LoVo,每天两次,没有作用活性。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

AZD4547 激酶活性:

使用浓度等于或低于相对Km 的ATP,测定AZD4547抑制 FGFR1-3的人类重组激酶活性的效果。
细胞实验:[1]
- 合并
  • Cell lines: KG1a, Sum52-PE, KMS11, 和MCF7
  • Concentrations: 溶于DMSO,终浓度为 ~1 μM
  • Incubation Time: 72 小时
  • Method: 使用多种浓度AZD4547处理细胞72小时。通过 MTS 增殖实验获得抗增殖的IC50值。荧光激活细胞分选(FACS)中,细胞与70%乙醇混合,然后与碘化丙啶/RNase A标记溶液温育。使用 FACSCalibur 仪器和CellQuest分析软件测定细胞周期谱。为了分析凋亡,轻轻收集细胞和培养基,离心,然后冲洗细胞颗粒。细胞进行Annexin膜联蛋白 V-异硫氰酸荧光素(FITC)染色和碘化丙啶吸收。使用FACSCalibur仪器测定 膜联蛋白 V染色阳性细胞比例,使用CellQuest分析软件进行象限分类。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 皮下注射LoVo, HCT-15, Calu-6, KMS11 或 KG1a的雌性Swiss衍生裸鼠和SCID小鼠
  • Dosages: 1.5-50 mg/kg
  • Administration: 口服饲喂,每天一次或两次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 92 mg/mL (198.45 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 463.57
化学式

C26H33N5O3

CAS号 1035270-39-3
储存条件 粉状
溶于溶剂
别名 ABSK 091

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02824133 Completed Drug: AZD4547 Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion|Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion Assistance Publique - Hôpitaux de Paris September 2015 Phase 1|Phase 2
NCT01824901 Completed Drug: docetaxel|Drug: AZD4547 Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group September 2013 Phase 1|Phase 2
NCT01795768 Unknown status Drug: AZD 4547 Gastric Cancer|Oesophageal Cancer|Breast Cancer|Squamous Cell Carcinoma of the Lung Royal Marsden NHS Foundation Trust|AstraZeneca September 2012 Phase 2
NCT01791985 Completed Drug: AZD4547 / anastrozole or letrozole Breast Cancer Imperial College London|Cancer Research UK|AstraZeneca July 2012 Phase 1|Phase 2
NCT01213160 Completed Drug: AZD4547 Cancer|Advanced Solid Malignancies AstraZeneca November 2010 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

相关FGFR产品

Tags: 购买AZD4547 | AZD4547供应商 | 采购AZD4547 | AZD4547价格 | AZD4547生产 | 订购AZD4547 | AZD4547代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID